Trials / Completed
CompletedNCT04451291
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
DSC-COVID-19: An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a research study to see how safe and effective decidual stromal cells are in treating patients with respiratory failure (breathing problem where not enough oxygen is passed from the lungs into the blood) caused by COVID-19.
Detailed description
COVID-19 viral infectious disease that has lead to high numbers of critically ill patients or death due to respiratory failure. Decidual Stromal Cells (DSC) may be useful in the treatment of acute respiratory distress syndrome (ARDS) by reducing lung inflammation and then time that patients require help with breathing (mechanical ventilation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Decidual Stromal Cells (DSC) | DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas. |
Timeline
- Start date
- 2020-09-25
- Primary completion
- 2023-11-07
- Completion
- 2023-11-07
- First posted
- 2020-06-30
- Last updated
- 2024-02-05
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04451291. Inclusion in this directory is not an endorsement.